Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KYMR
SellHot AirKymera Therapeutics, Inc. · Healthcare · United States · $9.7B · Avg Vol: $76M/d
COMPANY DESCRIPTION
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics that selectively degrade disease-causing proteins using its proprietary targeted protein degradation platform. Its competitive moat is its specialized DELigase™ platform and expertise in molecular glue degraders, targeting previously 'undruggable' proteins across oncology and immunology. Kymera is a cutting-edge biotechnology firm at the forefront of a promising new drug discovery modality.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 46.8M | 78.6M | 47.1M | 39.2M | -5.7% | 105.0M | 106.2M | 44.5M | 6.5% |
| EPS | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | — | -3.25 | -3.78 | -4.94 | — |
| Shares | — | 55.0M | 55.6M | 64.9M | 81.3M | +47.8% | 82.3M | — | — | — |
| Debt | — | 17.3M | 84.7M | 87.8M | 82.3M | 68.0% | 78.6M | — | — | — |
| Equity | — | 490.2M | 395.0M | 835.6M | 1.6B | 47.7% | — | — | — | — |
| Op CF | — | -153.1M | -102.8M | -194.5M | -232.9M | — | -236.8M | — | — | — |
| Inv CF | — | 20.5M | 139.9M | -404.1M | -521.1M | — | — | — | — | — |
| Fin CF | — | 153.0M | 4.2M | 608.9M | 990.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KYMR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc.(you) | $9.7B | 21 | Sell |
| CYTK | Cytokinetics, Incorporated | $10.0B | 22 | Sell |
| IMVT | Immunovant, Inc. | $8.5B | 21 | Sell |
| IBRX | ImmunityBio, Inc. | $8.5B | 22 | Sell |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 24 | Sell |
| AXSM | Axsome Therapeutics, Inc. | $10.4B | 25 | Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| PCVX | Vaxcyte, Inc. | $8.9B | 28 | Sell |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 26 | Sell |
| SRRK | Scholar Rock Holding Corporation | $7.0B | 19 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%